Increasing Sensitivity of Nasopharyngeal Carcinoma Cells to Cisplatin
Author Information
Author(s): Xie Si Ming, Fang Wei Yi, Liu Zhen, Wang Shuang Xi, Li Xin, Liu Teng Fei, Xie Wei Bing, Yao Kai Tai
Primary Institution: Cancer Research Institute, Southern Medical University
Hypothesis
Can RNAi targeting ABCC2 increase the sensitivity of nasopharyngeal carcinoma cells to cisplatin?
Conclusion
Lentivirus-mediated RNAi silencing targeting ABCC2 can reverse drug resistance in nasopharyngeal carcinoma cells against cisplatin.
Supporting Evidence
- ABCC2 expression was reduced by more than 70% in CNE2 cell clones.
- Intracellular accumulation of cisplatin increased significantly in ABCC2-silenced cells.
- Cisplatin sensitivity increased by 78% to 83% in CNE2 cells with reduced ABCC2 expression.
Takeaway
Scientists found a way to make cancer cells more sensitive to a common drug by blocking a specific protein that helps the cancer cells resist the drug.
Methodology
Lentiviral vectors were used to express anti-ABCC2 siRNA in CNE2 cells, followed by in vitro and in vivo assays to assess cisplatin sensitivity.
Potential Biases
Potential bias in the selection of cell lines and the experimental conditions.
Limitations
The study primarily focused on a single cell line and may not generalize to all nasopharyngeal carcinoma cases.
Participant Demographics
Human nasopharyngeal carcinoma cell line CNE2 was used.
Statistical Information
P-Value
0.00056
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website